Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Inclusion Criteria (abbreviated):

Has AML as defined by World Health Organization
Has detectable disease following first-line therapy
Is ≥ 18 years of age.
Carries the human leukocyte antigen-A0201 (HLA-A*02:01) allele.
Has ECOG performance status of 0 to 1.
Has adequate absolute total lymphocyte count
Has adequate cardiac, renal, and liver organ function

Exclusion Criteria (abbreviated):

Has received AML-directed therapy or immunomodulatory therapy within a specified window prior to study entry.
Has received allogeneic hematopoietic cell transplant within 84 days, with ongoing GVHD, with recent DLI, or on active immunosuppression.
Has CNS involvement by tumor.
Has severe autoimmunity requiring immunomodulatory therapy.
Has active disseminated intravascular coagulation (DIC), bleeding or coagulopathy.
Has leukocytosis ≥ 20,000 blasts/μL despite hydroxyurea or has rapidly progressive disease
Has human immunodeficiency virus (HIV) infection, or any uncontrolled infection.
Female subjects are pregnant or breastfeeding; or are of childbearing potential and are unwilling to use protocol specified method of contraception.
Male subjects who have female partners of childbearing potential and are unwilling to use protocol specified method of contraception.